US-based Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Germnay-based Bayer AG, announced on Thursday that it has named Gustavo Pesquin as its new chief executive officer (CEO) effective 11 March 2023.
Pesquin has served as chief commercial officer at Amneal Pharmaceuticals, Inc. He has over 10 years of experience at Sanofi, where he served in leadership roles of increasing responsibility, including North America head for General Medicines and global head of the Diabetes and Cardiovascular Franchise. He has held the position of regional head, general manager, sales head and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group.
Pesquin holds an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and a bachelor's degree in Public and Business Administration from Universidad Nacional de Cuyo in Argentina.
Langhua Pharmaceutical passes US FDA's on-site inspection
Arecor signs collaboration deal with global pharma partner
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome
FDA accepts Alvotech and Teva's application for Eylea biosimilar
Owens & Minor launches ByramConnect digital health platform for diabetes management
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Teladoc Health to acquire Catapult Health to enhance integrated care offerings
NLS Pharmaceutics and Kadimastem announce shareholder approval for merger
ImmunoPrecise Antibodies announces development of AI-designed GLP-1 therapies for diabetes